SCHEMBL3265795

SCHEMBL3265795

Cc1nc2c(c(N3CCN(C)CC3)n1)CCC(C)(C)C2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HTR6 P50406 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 1/20 0.39
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
HTR2C P28335 1/20 0.37
GPR55 Q9Y2T6 2/20 0.37
HTR2A P28223 1/20 0.36
HRH4 Q9H3N8 3/20 0.36
PDE4B Q07343 1/20 0.36
HTR3E A5X5Y0 1/20 0.35
HTR3B O95264 1/20 0.35
HTR3A P46098 1/20 0.35
HTR3D Q70Z44 1/20 0.35
HTR3C Q8WXA8 1/20 0.35
ALOX15 P16050 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL605798 0.84 HRH4 (0.45) HRH4
SCHEMBL3262542 0.78 HRH4 (0.42) MEN1KMT2AALDH1A1HPGDHRH4
SCHEMBL604785 0.71 HRH4 (0.45) HRH4
SCHEMBL605965 0.69 HRH4 (0.43) HTR2CHTR2AHRH4HTR3A
SCHEMBL4049208 0.69 IDH1 (0.39) MEN1KMT2AALDH1A1HPGDPDE4B
SCHEMBL605217 0.68 HRH4 (0.43) HRH4
SCHEMBL602589 0.66 HRH4 (0.41) HTR2CHTR2AHRH4HTR3A
SCHEMBL603830 0.65 HRH3 (0.41) HRH4
SCHEMBL602670 0.64 HRH3 (0.55) HRH4
SCHEMBL9483593 0.64 MEN1 (0.45) MEN1KMT2AHTR6ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298289-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2010-11-25 US disclosed
EP-2209775-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB Pharma, S.A. (BE) 2010-07-28 EP disclosed
WO-2009047255-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS UCB PHARMA, S.A. (BE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298289-A1 HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS HRH4, HRH2, HRH3 MEN1 1111/4885KMT2A 802/4885HTR6 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.